BioVoice News October 2016 Issue 6 Volume 1 | Page 21

laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilities and end-to-end services required in the rapidly evolving biopharmaceutical industry. “ The company also did acquisition of Novella Clinical (Novella), a fullservice clinical research organization (CRO) focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors. By joining QuintilesIMS, Novella will be able to continue this specialized focus while at the same time leveraging company’s scale and resources to provide new global capabilities to its existing and future customers. Given the fact that the CRO industry has not been doing that well in last few years, has it really affected the company? We believe the industry backdrop for the CRO industry continues to be strong globally, as evidenced by our growth over the past several years. Our Indian workforce is a key contributor to the way in which QuintilesIMS supports both our global and local customers and our headcount in India has been growing over the last few years. Given the highly skilled talent, technological capabilities and experience available in India, we are uniquely positioned to emerge as a leading destination in the delivery of these services to global companies. We have a balanced portfolio of services, primarily in the product development space, which include biostatistics, data management, cardiac safety services, pharmacovigilance and IT services besides core clinical trials, and have had a strong presence in these areas for several Perceptions about clinical research in the country have been impacted by the developments of the last few years. There is a need to educate the general public about clinical research and about their rights and responsibilities of patients. years now. We are seeing growth in these services driven by a demand for customers to seek solutions from an organization that has a winning combination of global healthcare expertise and a strong technology base. How do you view the growt